Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Iterum Therapeutics plc logo — Iterum develops anti-infectives to combat multi-drug resista...

Iterum Therapeutics plc

Iterum develops anti-infectives to combat multi-drug resistant pathogens and serious infections inadequately addressed by current therapies.

Founded 2015 Ireland Ireland 16 employees Post-IPO Equity Total: $193.40M Health and Wellness, Pharmaceutical

General Information

Company Name Iterum Therapeutics plc
Founded Year 2015
Location Ireland Ireland
Founders / Decision Makers
Team member Team member
Employees 16
Industries Health and Wellness, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Iterum Therapeutics plc. To contact Iterum Therapeutics plc, visit iterumtx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Iterum Therapeutics plc compare?

A PDF of Iterum Therapeutics plc and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Iterum Therapeutics plc soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Iterum Therapeutics plc

Iterum Therapeutics plc, a Dublin-based pharmaceutical company established in 2015, is dedicated to tackling the pressing issue of multi-drug resistance (MDR) pathogens. The company's slogan emphasizes its focus on developing anti-infectives to combat MDR pathogens and serious infections inadequately addressed by current therapies. Iterum Therapeutics aims to improve the quality of life for patients suffering from severe and life-threatening diseases globally through its innovative approach. The organization's commitment to addressing unmet needs in the treatment of severe infections, as identified by the Centers for Disease Control and Prevention (CDC), sets it apart in the pharmaceutical industry. The company has recently secured a significant $35.00M post-IPO equity investment on 03 February 2021, illustrating the confidence of investors in Iterum Therapeutics' mission and potential. This substantial investment further validates the market's recognition of the company's efforts to combat MDR pathogens and improve treatment options for serious infections. With its headquarters in Ireland, Iterum Therapeutics is well-positioned to advance its clinical-stage pharmaceutical developments and make a meaningful impact on global healthcare.

Business keywords: anti-infectives, multi-drug resistant pathogens, serious infections, clinical-stage pharmaceutical company, innovative treatments, multi-drug resistance (MDR), patient quality of life, severe infections, drug development, anti-microbial resistance, CDC, Dublin-based company

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $35.00M -
03 Feb 2021
Post IPO Equity $51.90M 2
RA Capital Management Sarissa Capital
RA Capital Management, Sarissa Capital
17 Jan 2020
Grant $1.50M 1
CARB-X
CARB-X
01 Jul 2017
Series B $65.00M 9
Advent Life Sciences Canaan Partners New Leaf Venture Partners
Advent Life Sciences, Canaan Partners +7
19 May 2017
Series A $40.00M 4
Canaan Partners New Leaf Venture Partners Frazier Healthcare Partners
Canaan Partners, New Leaf Venture Partners +2
24 Mar 2016
Venture Round Undisclosed 1
Sofinnova Investments
Sofinnova Investments
01 Jan 2015

Iterum Therapeutics plc Alternatives & Competitors

View All Alternatives
Iterum Therapeutics plc vs
Adaptive Phage Therapeutics
Adaptive Phage Therapeutics United States

To save lives or restore health as a leader in safe, rapidly deployable, cost-effective cures for ba...

Acquired
28 employees
Biotechnology, Health Care
Iterum Therapeutics plc vs
Cerebral Therapeutics, Inc.
Cerebral Therapeutics, Inc. United States

A clinical stage pharmaceutical company developing innovative treatments for neurological disease.

Series C
22 employees
Biotechnology, Health Care
Iterum Therapeutics plc vs
Octagon Therapeutics
Octagon Therapeutics

Advancing antibiotic innovation for multi-drug resistant infections with a world-class team and stat...

Convertible Note
11-50 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Iterum Therapeutics plc

Iterum develops anti-infectives to combat multi-drug resistant pathogens and serious infections inadequately addressed by current therapies.
Iterum Therapeutics plc was founded in 2015.
Iterum Therapeutics plc is headquartered in Ireland.
Iterum Therapeutics plc operates in Health and Wellness and Pharmaceutical. Its work centres on anti-infectives, multi-drug resistant pathogens, serious infections and clinical-stage pharmaceutical company.
Iterum Therapeutics plc has approximately 16 employees.
Iterum Therapeutics plc has completed 6 funding rounds, raising a total of $193.40M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Iterum Therapeutics plc include Adaptive Phage Therapeutics, Cerebral Therapeutics, Inc., Octagon Therapeutics, Microbion Corporation, ObsEva SA. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Iterum Therapeutics plc and Adaptive Phage Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Iterum Therapeutics plc, https://bouncewatch.com/company/iterum-therapeutics, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout